Diamond-Blackfan anemia 3
diseaseOn this page
Also known as anaemia Diamond-Blackfan 3anemia Diamond-Blackfan 3DBA3Diamond-Blackfan anaemia caused by mutation in RPS24Diamond-Blackfan Anaemia type 3Diamond-Blackfan anemia caused by mutation in RPS24Diamond-Blackfan Anemia type 3RPS24 Diamond-Blackfan anaemiaRPS24 Diamond-Blackfan anemia
Summary
Diamond-Blackfan anemia 3 (MONDO:0012529) is a disease caused by RPS24 (GenCC Definitive), with 1 cohort gene.
At a glance
- Causal gene: RPS24 (GenCC Definitive)
- Cohort genes: 1
- ClinVar variants: 69
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | Diamond-Blackfan anemia 3 |
| Mondo ID | MONDO:0012529 |
| MeSH | C536355 |
| OMIM | 610629 |
| DOID | DOID:0111887 |
| NCIT | C176912 |
| UMLS | C1857719 |
| MedGen | 387892 |
| GARD | 0010241 |
| Is cancer (heuristic) | no |
Also known as: anaemia Diamond-Blackfan 3 · anemia Diamond-Blackfan 3 · DBA3 · Diamond-Blackfan anaemia caused by mutation in RPS24 · Diamond-Blackfan Anaemia type 3 · Diamond-Blackfan anemia 3 · Diamond-Blackfan anemia caused by mutation in RPS24 · Diamond-Blackfan Anemia type 3 · RPS24 Diamond-Blackfan anaemia · RPS24 Diamond-Blackfan anemia
Data availability: 69 ClinVar variants · 3 GenCC gene-disease records.
Disease family
Classification path: disease › human disease › disease by body system or component › hematologic disorder › anemia › pure red-cell aplasia › Diamond-Blackfan anemia › Diamond-Blackfan anemia 3
Related subtypes (21): Diamond-Blackfan anemia 1, Diamond-Blackfan anemia 14 with mandibulofacial dysostosis, Diamond-Blackfan anemia 2, Diamond-Blackfan anemia 15 with mandibulofacial dysostosis, Diamond-Blackfan anemia 4, Diamond-Blackfan anemia 5, Diamond-Blackfan anemia 6, Diamond-Blackfan anemia 7, Diamond-Blackfan anemia 8, Diamond-Blackfan anemia 9, Diamond-Blackfan anemia 10, Diamond-Blackfan anemia 11, Diamond-Blackfan anemia 12, Diamond-Blackfan anemia 13, Diamond-Blackfan anemia 21, Diamond-Blackfan anemia 18, Diamond-Blackfan anemia 19, Diamond-Blackfan anemia 20, Diamond-Blackfan anemia 16, Diamond-Blackfan anemia 17, Diamond-Blackfan anemia 22
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
69 retrieved; paginated sample, class counts are floors:
29 uncertain significance, 12 benign, 8 benign/likely benign, 8 likely benign, 5 pathogenic, 4 conflicting classifications of pathogenicity, 3 likely pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 88977 | NC_000010.11:g.78030403_78035536del | LOC130004144 | Pathogenic | no assertion criteria provided |
| 549764 | NM_033022.4(RPS24):c.148A>C (p.Thr50Pro) | RPS24 | Pathogenic | criteria provided, single submitter |
| 7245 | NM_033022.4(RPS24):c.316C>T (p.Gln106Ter) | RPS24 | Pathogenic | no assertion criteria provided |
| 7246 | NM_033022.4(RPS24):c.46C>T (p.Arg16Ter) | RPS24 | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 7247 | NM_033022.4(RPS24):c.4_6delinsTACGGATAG (p.Asn2delinsTyrGlyTer) | RPS24 | Pathogenic | no assertion criteria provided |
| 4282505 | NM_033022.4(RPS24):c.3G>C (p.Met1Ile) | LOC130004144 | Likely pathogenic | criteria provided, single submitter |
| 1162257 | NM_033022.4(RPS24):c.157del (p.Asp53fs) | RPS24 | Likely pathogenic | criteria provided, single submitter |
| 2504586 | NM_033022.4(RPS24):c.273del (p.Ala92fs) | RPS24 | Likely pathogenic | criteria provided, single submitter |
| 696301 | NM_033022.4(RPS24):c.3+7C>T | LOC130004144 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1121639 | NM_033022.4(RPS24):c.21C>T (p.Ile7=) | RPS24 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1327106 | NM_001142285.2(RPS24):c.799C>G (p.Pro267Ala) | RPS24 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 2762593 | NM_033022.4(RPS24):c.348A>G (p.Lys116=) | RPS24 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 1698829 | NM_033022.4(RPS24):c.3G>A (p.Met1Ile) | LOC130004144 | Uncertain significance | criteria provided, single submitter |
| 301087 | NM_033022.3(RPS24):c.-142A>G | LOC130004144 | Uncertain significance | criteria provided, single submitter |
| 3598084 | NM_033022.4(RPS24):c.-8T>A | LOC130004144 | Uncertain significance | criteria provided, single submitter |
| 3598092 | NM_033022.4(RPS24):c.-4C>G | LOC130004144 | Uncertain significance | criteria provided, single submitter |
| 877451 | NM_033022.3(RPS24):c.-47T>G | LOC130004144 | Uncertain significance | criteria provided, single submitter |
| 1013633 | NM_033022.4(RPS24):c.122G>A (p.Arg41Gln) | RPS24 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1048968 | NM_001142285.2(RPS24):c.526G>A (p.Val176Met) | RPS24 | Uncertain significance | criteria provided, single submitter |
| 1414909 | NM_033022.4(RPS24):c.23G>A (p.Arg8His) | RPS24 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 1442613 | NM_033022.4(RPS24):c.390+3dup | RPS24 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 2418834 | NM_033022.4(RPS24):c.4-3C>T | RPS24 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 2435480 | NM_033022.4(RPS24):c.149C>G (p.Thr50Ser) | RPS24 | Uncertain significance | criteria provided, single submitter |
| 2441880 | NM_001142285.2(RPS24):c.522del (p.Pro173_Trp174insTer) | RPS24 | Uncertain significance | criteria provided, single submitter |
| 2585257 | NM_033022.4(RPS24):c.155C>T (p.Pro52Leu) | RPS24 | Uncertain significance | criteria provided, single submitter |
| 2689885 | NM_033022.4(RPS24):c.390+4T>C | RPS24 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 3598100 | NM_033022.4(RPS24):c.11C>T (p.Thr4Ile) | RPS24 | Uncertain significance | criteria provided, single submitter |
| 3598115 | NM_033022.4(RPS24):c.220A>G (p.Met74Val) | RPS24 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 3598123 | NM_033022.4(RPS24):c.248A>G (p.Lys83Arg) | RPS24 | Uncertain significance | criteria provided, multiple submitters, no conflicts |
| 3598130 | NM_033022.4(RPS24):c.260C>T (p.Pro87Leu) | RPS24 | Uncertain significance | criteria provided, single submitter |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 5 · Orphanet: 1 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| RPS24 | Definitive | Unknown | Diamond-Blackfan anemia | 5 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| RPS24 | Orphanet:124 | Diamond-Blackfan anemia |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| RPS24 | HGNC:10411 | ENSG00000138326 | P62847 | Small ribosomal subunit protein eS24 | gencc,clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| RPS24 | Small ribosomal subunit protein eS24 | Component of the small ribosomal subunit. |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 1 | 1.8× | 0.558 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| RPS24 | Other/Unknown | no | Ribosomal_eS24, Ribosomal_uL23/eL15/eS24_sf, Ribosomal_eS24_CS |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| colonic mucosa | 1 |
| ganglionic eminence | 1 |
| mucosa of sigmoid colon | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| RPS24 | 288 | ubiquitous | marker | ganglionic eminence, mucosa of sigmoid colon, colonic mucosa |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| RPS24 | 974 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| RPS24 | P62847 | 214 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 50. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Eukaryotic Translation Initiation | 1 | 308.6× | 0.016 | RPS24 |
| Cap-dependent Translation Initiation | 1 | 308.6× | 0.016 | RPS24 |
| SARS-CoV-1 modulates host translation machinery | 1 | 308.6× | 0.016 | RPS24 |
| Eukaryotic Translation Elongation | 1 | 278.5× | 0.016 | RPS24 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 1 | 271.9× | 0.016 | RPS24 |
| Nonsense-Mediated Decay (NMD) | 1 | 233.1× | 0.016 | RPS24 |
| SARS-CoV-2 modulates host translation machinery | 1 | 223.9× | 0.016 | RPS24 |
| Influenza Viral RNA Transcription and Replication | 1 | 215.5× | 0.016 | RPS24 |
| Formation of the ternary complex, and subsequently, the 43S complex | 1 | 215.5× | 0.016 | RPS24 |
| Selenoamino acid metabolism | 1 | 196.9× | 0.016 | RPS24 |
| Translation initiation complex formation | 1 | 190.3× | 0.016 | RPS24 |
| Ribosomal scanning and start codon recognition | 1 | 190.3× | 0.016 | RPS24 |
| Influenza Infection | 1 | 175.7× | 0.016 | RPS24 |
| SARS-CoV-1-host interactions | 1 | 175.7× | 0.016 | RPS24 |
| Cellular response to starvation | 1 | 165.5× | 0.016 | RPS24 |
| rRNA processing in the nucleus and cytosol | 1 | 160.8× | 0.016 | RPS24 |
| rRNA processing | 1 | 146.4× | 0.016 | RPS24 |
| SARS-CoV-1 Infection | 1 | 142.8× | 0.016 | RPS24 |
| Peptide chain elongation | 1 | 126.9× | 0.016 | RPS24 |
| Viral mRNA Translation | 1 | 126.9× | 0.016 | RPS24 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | 1 | 125.5× | 0.016 | RPS24 |
| Signaling by ROBO receptors | 1 | 124.1× | 0.016 | RPS24 |
| Selenocysteine synthesis | 1 | 120.2× | 0.016 | RPS24 |
| Eukaryotic Translation Termination | 1 | 120.2× | 0.016 | RPS24 |
| SARS-CoV-2-host interactions | 1 | 119.0× | 0.016 | RPS24 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 1 | 117.7× | 0.016 | RPS24 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | 1 | 117.7× | 0.016 | RPS24 |
| Formation of a pool of free 40S subunits | 1 | 112.0× | 0.016 | RPS24 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | 1 | 110.9× | 0.016 | RPS24 |
| L13a-mediated translational silencing of Ceruloplasmin expression | 1 | 101.1× | 0.016 | RPS24 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| erythrocyte homeostasis | 1 | 1296.3× | 0.004 | RPS24 |
| ribosomal small subunit biogenesis | 1 | 227.7× | 0.009 | RPS24 |
| cytoplasmic translation | 1 | 185.2× | 0.009 | RPS24 |
| rRNA processing | 1 | 141.6× | 0.009 | RPS24 |
| translation | 1 | 102.8× | 0.010 | RPS24 |
Therapeutics
Drug target analysis
Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 0
Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Genes with an approved drug
The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.
| Symbol | Example approved molecule |
|---|---|
| RPS24 | GENTAMICIN SULFATE |
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| RPS24 | 1 | 4 |
Drugs targeting cohort genes (top 30)
| Molecule | Max phase | Targets in cohort |
|---|---|---|
| GENTAMICIN SULFATE | 4 | RPS24 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| RPS24 | 90 | Binding:90 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
1 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
| Compound | Max phase | Cohort target (bioactivity) |
|---|---|---|
| GENTAMICIN SULFATE | 4 | RPS24 |
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 1 | RPS24 |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 0 |
Undrugged target profiles
0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: RPS24